Enfuvirtide Acetate (T-20)
エイリアス:Fuzeon
順序:CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
カス番号. : 159519-65-0
分子式 : C204H301N51O64
分子量 : 4492
純度 (HPLC) : 98.0%分.
外観 : White to off-white amorphous solid
単一の不純物 (HPLC) : 0.5%最大
アミノ酸組成 : 理論値の±10%
ペプチド含有量 (N%) : ≧80.0%
水分含有量 (カール・フィッシャー) : ≤8.0%
トリフルオロ酢酸含有量(HPIC) : ≤12.0%
MS (ESI) : 一貫性のある
マスバランス : 95.0～105.0%
学年 : 医薬品グレード
ストレージ: 閉店, 下に 2 ～8℃保存
使用法 : Treatment option for patients suffering from HIV/AIDS.
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Enfuvirtide (宿) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
